DexCom, Inc. (DXCM) to Post FY2018 Earnings of ($0.09) Per Share, Jefferies Financial Group Forecasts

DexCom, Inc. (NASDAQ:DXCM) – Research analysts at Jefferies Financial Group raised their FY2018 earnings per share estimates for DexCom in a research report issued on Tuesday, November 6th. Jefferies Financial Group analyst R. Denhoy now anticipates that the medical device company will post earnings of ($0.09) per share for the year, up from their previous estimate of ($0.25). Jefferies Financial Group currently has a “Buy” rating and a $148.00 target price on the stock. Jefferies Financial Group also issued estimates for DexCom’s Q4 2018 earnings at $0.17 EPS, Q1 2019 earnings at $0.00 EPS, Q2 2019 earnings at $0.19 EPS, FY2019 earnings at $0.40 EPS and FY2020 earnings at $0.30 EPS.

Other research analysts have also recently issued reports about the stock. Stephens reissued a “buy” rating and set a $135.00 price objective on shares of DexCom in a research note on Thursday, August 2nd. Bank of America raised their price objective on shares of DexCom from $106.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Canaccord Genuity raised their price objective on shares of DexCom from $105.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Oppenheimer set a $125.00 price objective on shares of DexCom and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Finally, BidaskClub cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 31st. Eight analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. DexCom has a consensus rating of “Buy” and a consensus price target of $132.50.

Shares of DXCM opened at $148.41 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 4.89 and a quick ratio of 4.62. DexCom has a 1-year low of $49.17 and a 1-year high of $152.14. The company has a market cap of $11.74 billion, a PE ratio of -255.88 and a beta of 0.60.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Tuesday, November 6th. The medical device company reported $0.17 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.29. DexCom had a net margin of 4.72% and a negative return on equity of 3.08%. The business had revenue of $266.70 million during the quarter, compared to analysts’ expectations of $242.72 million. The firm’s revenue for the quarter was up 44.5% on a year-over-year basis.

A number of hedge funds have recently added to or reduced their stakes in DXCM. Waddell & Reed Financial Inc. boosted its holdings in shares of DexCom by 164.8% in the 2nd quarter. Waddell & Reed Financial Inc. now owns 569,331 shares of the medical device company’s stock valued at $54,075,000 after purchasing an additional 354,331 shares during the last quarter. UBS Group AG boosted its holdings in shares of DexCom by 76.3% in the 1st quarter. UBS Group AG now owns 15,926 shares of the medical device company’s stock valued at $1,181,000 after purchasing an additional 6,890 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of DexCom by 5.9% in the 2nd quarter. BlackRock Inc. now owns 4,116,421 shares of the medical device company’s stock valued at $390,978,000 after purchasing an additional 228,933 shares during the last quarter. Macquarie Group Ltd. boosted its holdings in shares of DexCom by 14.4% in the 2nd quarter. Macquarie Group Ltd. now owns 236,341 shares of the medical device company’s stock valued at $22,448,000 after purchasing an additional 29,825 shares during the last quarter. Finally, Federated Investors Inc. PA boosted its holdings in shares of DexCom by 97.1% in the 2nd quarter. Federated Investors Inc. PA now owns 460,209 shares of the medical device company’s stock valued at $43,710,000 after purchasing an additional 226,740 shares during the last quarter.

In other DexCom news, EVP Steven Robert Pacelli sold 3,114 shares of DexCom stock in a transaction that occurred on Tuesday, October 23rd. The shares were sold at an average price of $128.85, for a total value of $401,238.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Patrick Michael Murphy sold 400 shares of DexCom stock in a transaction that occurred on Wednesday, October 10th. The stock was sold at an average price of $122.20, for a total transaction of $48,880.00. The disclosure for this sale can be found here. Insiders sold a total of 157,892 shares of company stock valued at $21,864,030 over the last ninety days. 1.80% of the stock is owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Story: Intrinsic Value and Stock Selection

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply